Previous close | 0.4309 |
Open | 0.4200 |
Bid | 0.4000 x 200 |
Ask | 0.4044 x 400 |
Day's range | 0.3855 - 0.4377 |
52-week range | 0.1620 - 1.7170 |
Volume | |
Avg. volume | 4,717,040 |
Market cap | 29.991M |
Beta (5Y monthly) | -0.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.2100 |
Earnings date | 14 May 2024 - 18 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute has awarded a $3.6 million grant for a clinical trial to evaluate the Selective Cytopheretic Device Adult (SCD-ADULT, a member of the Company’s Quelimmune™ product family) as a bridgin
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update. “It was exceptionally exciting to receive our first FDA approval for Quelimmune™, which is now available for treating critically
DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time. The formal presentation will be followed by a hosted question-and-answer session. Investors int